BRPI0613861B8 - derivados de isoquinolona piperidinil-substituídos como inibidores de rho-cinase - Google Patents
derivados de isoquinolona piperidinil-substituídos como inibidores de rho-cinaseInfo
- Publication number
- BRPI0613861B8 BRPI0613861B8 BRPI0613861A BRPI0613861A BRPI0613861B8 BR PI0613861 B8 BRPI0613861 B8 BR PI0613861B8 BR PI0613861 A BRPI0613861 A BR PI0613861A BR PI0613861 A BRPI0613861 A BR PI0613861A BR PI0613861 B8 BRPI0613861 B8 BR PI0613861B8
- Authority
- BR
- Brazil
- Prior art keywords
- rho
- piperidinyl
- kinase inhibitors
- substituted isoquinolone
- isoquinolone derivatives
- Prior art date
Links
- VDBNYAPERZTOOF-UHFFFAOYSA-N isoquinolin-1(2H)-one Chemical class C1=CC=C2C(=O)NC=CC2=C1 VDBNYAPERZTOOF-UHFFFAOYSA-N 0.000 title abstract 3
- 239000003590 rho kinase inhibitor Substances 0.000 title abstract 2
- 102000000568 rho-Associated Kinases Human genes 0.000 abstract 2
- 108010041788 rho-Associated Kinases Proteins 0.000 abstract 2
- 102000011131 Myosin-Light-Chain Phosphatase Human genes 0.000 abstract 1
- 108010037801 Myosin-Light-Chain Phosphatase Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 150000002537 isoquinolines Chemical class 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000026731 phosphorylation Effects 0.000 abstract 1
- 238000006366 phosphorylation reaction Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Reproductive Health (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gynecology & Obstetrics (AREA)
- Virology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05016154 | 2005-07-26 | ||
| EP05016154.6 | 2005-07-26 | ||
| PCT/EP2006/007139 WO2007012421A1 (en) | 2005-07-26 | 2006-07-20 | Piperidinyl-substituted isoquinolone derivatives as rho-kinase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0613861A2 BRPI0613861A2 (pt) | 2011-02-15 |
| BRPI0613861B1 BRPI0613861B1 (pt) | 2019-12-10 |
| BRPI0613861B8 true BRPI0613861B8 (pt) | 2021-05-25 |
Family
ID=34979095
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0613861A BRPI0613861B8 (pt) | 2005-07-26 | 2006-07-20 | derivados de isoquinolona piperidinil-substituídos como inibidores de rho-cinase |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US8188117B2 (enExample) |
| EP (2) | EP2385047B1 (enExample) |
| JP (1) | JP5060478B2 (enExample) |
| KR (1) | KR101373535B1 (enExample) |
| CN (1) | CN101228149B (enExample) |
| AR (1) | AR054868A1 (enExample) |
| AU (1) | AU2006274245B2 (enExample) |
| BR (1) | BRPI0613861B8 (enExample) |
| CA (1) | CA2615577C (enExample) |
| CR (1) | CR9603A (enExample) |
| DK (1) | DK1910333T3 (enExample) |
| DO (1) | DOP2006000178A (enExample) |
| EC (1) | ECSP088135A (enExample) |
| ES (1) | ES2423006T3 (enExample) |
| GT (1) | GT200600328A (enExample) |
| IL (1) | IL188702A (enExample) |
| MA (1) | MA29636B1 (enExample) |
| MX (1) | MX2008001053A (enExample) |
| MY (1) | MY148479A (enExample) |
| NI (1) | NI200800025A (enExample) |
| NO (1) | NO341888B1 (enExample) |
| NZ (1) | NZ565668A (enExample) |
| PE (1) | PE20070217A1 (enExample) |
| PT (1) | PT1910333E (enExample) |
| RU (1) | RU2414467C2 (enExample) |
| TN (1) | TNSN08039A1 (enExample) |
| TW (1) | TWI383979B (enExample) |
| UA (1) | UA93882C2 (enExample) |
| UY (1) | UY29697A1 (enExample) |
| WO (1) | WO2007012421A1 (enExample) |
| ZA (1) | ZA200710951B (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ565040A (en) | 2005-06-28 | 2010-05-28 | Sanofi Aventis | Isoquinoline derivatives as inhibitors of RHO-kinase |
| RS52241B (sr) | 2005-07-26 | 2012-10-31 | Sanofi | Derivati cikloheksilamin izohinolona kao inhibitori rho-kinaze |
| TW200738682A (en) * | 2005-12-08 | 2007-10-16 | Organon Nv | Isoquinoline derivatives |
| CA2663193A1 (en) * | 2006-09-11 | 2008-03-20 | N.V. Organon | 2-(1-oxo-1h-isoquinolin-2-yl)acetamide derivatives |
| WO2008077556A1 (en) | 2006-12-27 | 2008-07-03 | Sanofi-Aventis | Cycloalkylamine substituted isoquinoline and isoquinolinone derivatives |
| BRPI0721180A2 (pt) | 2006-12-27 | 2014-03-18 | Sanofi Aventis | Derivados de isoquinolina substituídos com cicloalquilamina |
| NZ577981A (en) | 2006-12-27 | 2011-12-22 | Sanofi Aventis | Substituted isoquinoline and isoquinolinone derivatives as inhibitors of rho-kinase |
| EP2114920A1 (en) | 2006-12-27 | 2009-11-11 | Sanofi-Aventis | Substituted isoquinoline and isoquinolinone derivatives |
| EP2125745B1 (en) | 2006-12-27 | 2017-02-22 | Sanofi | Cycloalkylamine substituted isoquinolone derivatives |
| MX2009005862A (es) | 2006-12-27 | 2009-06-17 | Sanofi Aventis | Nuevos derivados de isoquinolina e isoquinolinona sustituidos. |
| CN103432133B (zh) * | 2007-01-22 | 2016-08-10 | Gtx公司 | 核受体结合剂的用途 |
| US9623021B2 (en) * | 2007-01-22 | 2017-04-18 | Gtx, Inc. | Nuclear receptor binding agents |
| US9604931B2 (en) | 2007-01-22 | 2017-03-28 | Gtx, Inc. | Nuclear receptor binding agents |
| JP2011507921A (ja) * | 2007-12-26 | 2011-03-10 | サノフィ−アベンティス | ６−置換−１−（２ｈ）−イソキノリノンの製造法 |
| CA2728137C (en) | 2008-06-24 | 2016-10-18 | Sanofi-Aventis | Substituted isoquinolines and isoquinolinones as rho kinase inhibitors |
| CA2728128C (en) | 2008-06-24 | 2016-06-07 | Sanofi-Aventis | 6-substituted isoquinolines and isoquinolinones |
| CA2728123C (en) | 2008-06-24 | 2017-02-21 | Sanofi-Aventis | Bi- and polycyclic substituted isoquinoline and isoquinolinone derivatives |
| US9865233B2 (en) | 2008-12-30 | 2018-01-09 | Intel Corporation | Hybrid graphics display power management |
| EP2488520B1 (en) * | 2009-10-13 | 2015-09-02 | Merck Sharp & Dohme B.V. | Condensed azine-derivatives for the treatment of diseases related to the acetylcholine receptor |
| EP2729007A1 (de) * | 2011-07-04 | 2014-05-14 | Bayer Intellectual Property GmbH | Verwendung substituierter isochinolinone, isochinolindione, isochinolintrione und dihydroisochinolinone oder jeweils deren salze als wirkstoffe gegen abiotischen pflanzenstress |
| KR101959711B1 (ko) | 2011-07-08 | 2019-03-19 | 사노피 | 치환된 페닐 화합물 |
| CN103781778B (zh) * | 2011-07-08 | 2015-10-07 | 赛诺菲 | 6-(哌啶-4-基氧基)-2h-异喹啉-1-酮盐酸盐的结晶性溶剂化物 |
| EP2729461B1 (en) * | 2011-07-08 | 2016-01-20 | Sanofi | Polymorphs of 6-(piperidin-4-yloxy)-2h-isoquinolin-1-one hydrochloride |
| EP3141235A1 (en) | 2012-12-06 | 2017-03-15 | IP Gesellschaft für Management mbH | N-(6-((2r,3s)-3,4-dihydroxybutan-2-yloxy)-2-(4-fluorobenzylthio)pyrimidin-4-yl)-3-methylazetidine-l -sulfonamide |
| LT3057586T (lt) | 2013-10-18 | 2020-03-10 | Celgene Quanticel Research, Inc. | Bromodomeno inhibitoriai |
| RS61519B1 (sr) | 2013-11-18 | 2021-03-31 | Forma Therapeutics Inc | Sastavi tetrahidrohinolina kao inhibitori bet bromodomena |
| FR3017868A1 (fr) | 2014-02-21 | 2015-08-28 | Servier Lab | Derives d'isoquinoleine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| EP3237397B1 (en) | 2014-12-24 | 2018-11-21 | Gilead Sciences, Inc. | Isoquinoline compounds for the treatment of hiv |
| AU2015371255B2 (en) | 2014-12-24 | 2018-09-27 | Gilead Sciences, Inc. | Fused pyrimidine compounds for the treatment of HIV |
| TW202237569A (zh) | 2014-12-24 | 2022-10-01 | 美商基利科學股份有限公司 | 喹唑啉化合物 |
| AR104259A1 (es) | 2015-04-15 | 2017-07-05 | Celgene Quanticel Res Inc | Inhibidores de bromodominio |
| HK1255034A1 (zh) | 2015-07-01 | 2019-08-02 | Crinetics Pharmaceuticals, Inc. | 生长抑素调节剂及其用途 |
| WO2017174879A1 (en) * | 2016-04-06 | 2017-10-12 | University Of Oulu | Compounds for use in the treatment of cancer |
| AU2017252276A1 (en) | 2016-04-18 | 2018-11-15 | Celgene Quanticel Research, Inc. | Therapeutic compounds |
| US10150754B2 (en) | 2016-04-19 | 2018-12-11 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| CN106632258B (zh) * | 2016-12-15 | 2019-04-02 | 三峡大学 | 四氢异喹啉-2-基芳氧基苯氧基烷基酮化合物及其应用 |
| EP3658560A4 (en) | 2017-07-25 | 2021-01-06 | Crinetics Pharmaceuticals, Inc. | SOMATOSTAT IN MODULATORS AND USES THEREOF |
| CA3236332A1 (en) | 2021-10-30 | 2023-05-04 | Ziev B. Moses | Treatments for disturbed cerebral homeostasis |
| JP2025525162A (ja) * | 2022-08-01 | 2025-08-01 | ヴァロ ヘルス インコーポレイテッド | ６－置換－１－（２ｈ）－イソキノリノン及び中間体化合物の製造方法 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2485537B2 (fr) | 1977-04-13 | 1986-05-16 | Anvar | Dipyrido(4,3-b)(3,4-f)indoles, procede d'obtention, application therapeutique et compositions pharmaceutiques les contenant |
| JPH06501921A (ja) | 1990-07-31 | 1994-03-03 | イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー | 選択されたハロカーボンの触媒平衡化 |
| US5480883A (en) | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| GB9516709D0 (en) | 1995-08-15 | 1995-10-18 | Zeneca Ltd | Medicament |
| WO1997009311A1 (de) * | 1995-09-07 | 1997-03-13 | F. Hoffmann-La Roche Ag | Neue 4-(oxyalkoxyphenyl)-3-oxy-piperidine zur behandlung von herz- und niereninsuffizienz |
| ZA9610741B (en) | 1995-12-22 | 1997-06-24 | Warner Lambert Co | 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists |
| JP3669711B2 (ja) | 1996-08-12 | 2005-07-13 | 三菱ウェルファーマ株式会社 | Ｒｈｏキナーゼ阻害剤を含有する医薬 |
| JPH1087629A (ja) | 1996-09-18 | 1998-04-07 | Fujisawa Pharmaceut Co Ltd | 新規イソキノリン誘導体、およびその医薬用途 |
| WO1999011642A1 (en) | 1997-08-29 | 1999-03-11 | Zeneca Limited | Aminometyl oxooxazolidinyl benzene derivatives |
| TW575567B (en) | 1998-10-23 | 2004-02-11 | Akzo Nobel Nv | Serine protease inhibitor |
| GB9912701D0 (en) | 1999-06-01 | 1999-08-04 | Smithkline Beecham Plc | Novel compounds |
| US6541456B1 (en) | 1999-12-01 | 2003-04-01 | Isis Pharmaceuticals, Inc. | Antimicrobial 2-deoxystreptamine compounds |
| IL150650A0 (en) | 2000-01-20 | 2003-02-12 | Eisai Co Ltd | Piperidine derivatives and pharmaceutical compositions containing the same |
| US7217722B2 (en) | 2000-02-01 | 2007-05-15 | Kirin Beer Kabushiki Kaisha | Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same |
| US20040171533A1 (en) | 2000-02-29 | 2004-09-02 | Barbara Zehentner | Methods and compositions for regulating adiopocytes |
| GB0004887D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| AR033517A1 (es) | 2000-04-08 | 2003-12-26 | Astrazeneca Ab | Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos |
| GB0013060D0 (en) | 2000-05-31 | 2000-07-19 | Astrazeneca Ab | Chemical compounds |
| AU2001296008A1 (en) | 2000-10-27 | 2002-05-06 | Takeda Chemical Industries Ltd. | Process for preparing substituted aromatic compounds and intermediates therefor |
| JP2004520347A (ja) | 2001-01-15 | 2004-07-08 | グラクソ グループ リミテッド | Ｌｄｌ−受容体発現のインデューサーとしてのアリールピペリジンおよびピペラジン誘導体 |
| SE0101038D0 (sv) | 2001-03-23 | 2001-03-23 | Astrazeneca Ab | Novel compounds |
| WO2002088101A2 (en) | 2001-04-27 | 2002-11-07 | Vertex Pharmaceuticals Incorporated | Inhibitors of bace |
| JPWO2002100833A1 (ja) * | 2001-06-12 | 2004-09-24 | 住友製薬株式会社 | Ｒｈｏキナーゼ阻害剤 |
| GB0117899D0 (en) | 2001-07-23 | 2001-09-12 | Astrazeneca Ab | Chemical compounds |
| WO2003024450A1 (en) | 2001-09-20 | 2003-03-27 | Eisai Co., Ltd. | Methods for treating prion diseases |
| SE0104340D0 (sv) | 2001-12-20 | 2001-12-20 | Astrazeneca Ab | New compounds |
| JPWO2004009555A1 (ja) * | 2002-07-22 | 2005-11-17 | 旭化成ファーマ株式会社 | ５−置換イソキノリン誘導体 |
| CA2502583A1 (en) | 2002-09-12 | 2004-03-25 | Kirin Beer Kabushiki Kaisha | Isoquinoline derivatives having kinase inhibitory activity and medicament containing the same |
| US20050014783A1 (en) | 2003-05-29 | 2005-01-20 | Schering Aktiengesellschaft | Use of Rho-kinase inhibitors in the treatment of aneurysm and cardiac hypertrophy |
| EP1638939A2 (en) | 2003-06-24 | 2006-03-29 | Neurosearch A/S | Aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| CA2539479C (en) | 2003-09-23 | 2010-07-06 | Merck & Co., Inc. | Isoquinoline potassium channel inhibitors |
| CA2539814C (en) | 2003-09-23 | 2010-07-06 | Merck & Co., Inc. | Isoquinolinone potassium channel inhibitors |
| US20050067037A1 (en) | 2003-09-30 | 2005-03-31 | Conocophillips Company | Collapse resistant composite riser |
| WO2005035516A1 (ja) | 2003-10-10 | 2005-04-21 | Ono Pharmaceutical Co., Ltd. | 新規縮合複素環化合物およびその用途 |
| JP2007008816A (ja) * | 2003-10-15 | 2007-01-18 | Ube Ind Ltd | 新規イソキノリン誘導体 |
| US7449477B2 (en) | 2003-11-25 | 2008-11-11 | Eli Lilly And Company | 7-phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt (protein kinase B) |
| WO2005074535A2 (en) | 2004-01-30 | 2005-08-18 | Eisai Co., Ltd. | Cholinesterase inhibitors for spinal cord disorders |
| WO2005087226A1 (en) | 2004-03-05 | 2005-09-22 | Eisai Co., Ltd. | Cadasil treatment with cholinesterase inhibitors |
| SE0400850D0 (sv) | 2004-03-30 | 2004-03-31 | Astrazeneca Ab | Novel Compounds |
| US7517991B2 (en) | 2004-10-12 | 2009-04-14 | Bristol-Myers Squibb Company | N-sulfonylpiperidine cannabinoid receptor 1 antagonists |
| RS52241B (sr) | 2005-07-26 | 2012-10-31 | Sanofi | Derivati cikloheksilamin izohinolona kao inhibitori rho-kinaze |
| TW200745101A (en) | 2005-09-30 | 2007-12-16 | Organon Nv | 9-Azabicyclo[3.3.1]nonane derivatives |
| US7618985B2 (en) | 2005-12-08 | 2009-11-17 | N.V. Organon | Isoquinoline derivatives |
| TW200738682A (en) * | 2005-12-08 | 2007-10-16 | Organon Nv | Isoquinoline derivatives |
| US7893088B2 (en) | 2006-08-18 | 2011-02-22 | N.V. Organon | 6-substituted isoquinoline derivatives |
| MX2009005862A (es) | 2006-12-27 | 2009-06-17 | Sanofi Aventis | Nuevos derivados de isoquinolina e isoquinolinona sustituidos. |
| WO2008077556A1 (en) | 2006-12-27 | 2008-07-03 | Sanofi-Aventis | Cycloalkylamine substituted isoquinoline and isoquinolinone derivatives |
-
2006
- 2006-07-20 NZ NZ565668A patent/NZ565668A/en not_active IP Right Cessation
- 2006-07-20 EP EP11176273.8A patent/EP2385047B1/en active Active
- 2006-07-20 CA CA2615577A patent/CA2615577C/en active Active
- 2006-07-20 WO PCT/EP2006/007139 patent/WO2007012421A1/en not_active Ceased
- 2006-07-20 CN CN2006800271613A patent/CN101228149B/zh active Active
- 2006-07-20 MX MX2008001053A patent/MX2008001053A/es active IP Right Grant
- 2006-07-20 KR KR1020087002168A patent/KR101373535B1/ko active Active
- 2006-07-20 AU AU2006274245A patent/AU2006274245B2/en active Active
- 2006-07-20 EP EP06776306.0A patent/EP1910333B1/en active Active
- 2006-07-20 PT PT67763060T patent/PT1910333E/pt unknown
- 2006-07-20 ES ES06776306T patent/ES2423006T3/es active Active
- 2006-07-20 BR BRPI0613861A patent/BRPI0613861B8/pt active IP Right Grant
- 2006-07-20 JP JP2008523188A patent/JP5060478B2/ja active Active
- 2006-07-20 DK DK06776306.0T patent/DK1910333T3/da active
- 2006-07-20 NI NI200800025A patent/NI200800025A/es unknown
- 2006-07-20 UA UAA200802430A patent/UA93882C2/ru unknown
- 2006-07-20 RU RU2008106950/04A patent/RU2414467C2/ru active
- 2006-07-24 MY MYPI20063515A patent/MY148479A/en unknown
- 2006-07-24 TW TW095126882A patent/TWI383979B/zh active
- 2006-07-24 GT GT200600328A patent/GT200600328A/es unknown
- 2006-07-25 PE PE2006000896A patent/PE20070217A1/es not_active Application Discontinuation
- 2006-07-25 AR ARP060103199A patent/AR054868A1/es active IP Right Grant
- 2006-07-25 DO DO2006000178A patent/DOP2006000178A/es unknown
- 2006-07-26 UY UY29697A patent/UY29697A1/es not_active Application Discontinuation
-
2007
- 2007-12-18 CR CR9603A patent/CR9603A/es not_active Application Discontinuation
- 2007-12-18 ZA ZA200701095A patent/ZA200710951B/xx unknown
-
2008
- 2008-01-10 IL IL188702A patent/IL188702A/en active IP Right Grant
- 2008-01-18 MA MA30583A patent/MA29636B1/fr unknown
- 2008-01-25 EC EC2008008135A patent/ECSP088135A/es unknown
- 2008-01-25 US US12/019,866 patent/US8188117B2/en active Active
- 2008-01-25 TN TNP2008000039A patent/TNSN08039A1/en unknown
- 2008-02-22 NO NO20080963A patent/NO341888B1/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0613861B8 (pt) | derivados de isoquinolona piperidinil-substituídos como inibidores de rho-cinase | |
| TW200738678A (en) | Isoquinoline derivatives | |
| ATE554072T1 (de) | Cycloalkylaminsubstituierte isochinolinderivate | |
| CO6210725A2 (es) | Derivados de isoquinolona e isoquinolinona sustituidos con cicloalquilamina | |
| MY155009A (en) | Cycloalkylamine substituted isoquinolone derivatives | |
| MY148902A (en) | Substituted isoquinolines and their use as rho-kinase inhibitors | |
| MY154767A (en) | Cycloalkyamine substituted isoquinoline and isoquinolinone derivatives | |
| TNSN08038A1 (en) | Cyclohexylamin isoquinolone derivatives as rho-kinase inhibitors | |
| MY155279A (en) | Substituted isoquinoline and isoquinolinone derivatives | |
| NI200900107A (es) | Derivados de isoquinolina e isoquinolinona sustituidos en calidad de inhibidores de rho-quinasa. | |
| MY157330A (en) | Substituted isoquinolinones as rho kinase inhibitors | |
| UY29698A1 (es) | Derivados de ciclohexilaminisoquinolona |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 10/12/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 10/12/2019, OBSERVADAS AS CONDICOES LEGAIS |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/07/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |